Adjuvant colon cancer chemotherapy: Where we are and where we'll go

Cancer Treatment Reviews

Volumn 36, Issue SUPPL. 3, 2010, Pages

  Lombardi, L ^a   Morelli, F ^a   Cinieri, S ^b   Santini, D ^c   Silvestris, N ^d   Fazio, N ^e   Orlando, L ^b   Tonini, G ^c   Colucci, G ^d   Maiello, E ^a  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^b PERRINO HOSPITAL   (Italy)

^c UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^d NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^e EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Adjuvant chemotherapy; Colon cancer; Molecular markers; Trial

Indexed keywords

B RAF KINASE; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; GUANYLATE CYCLASE; GUANYLATE CYCLASE 2; IRINOTECAN; K RAS PROTEIN; LEVAMISOLE; OXALIPLATIN; PROTEIN P53; SEMUSTINE; TEGAFUR; TUMOR MARKER; UNCLASSIFIED DRUG; VINCRISTINE;

ADD ON THERAPY; ANTIANGIOGENIC THERAPY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHROMOSOME 18Q; CHROMOSOME LOSS; COLON CANCER; COLORECTAL CANCER; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; GENE MUTATION; HAND FOOT SYNDROME; HETEROZYGOSITY; HUMAN; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PREDICTION; PROGNOSIS; RISK REDUCTION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; FLUOROURACIL; HUMANS; LEVAMISOLE; LOSS OF HETEROZYGOSITY; LYMPHATIC METASTASIS; MICROSATELLITE INSTABILITY; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 78649751640     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/S0305-7372(10)70018-9     Document Type: Article

References (66)

1. American Cancer Society Cancer Facts & Figures 2008 2008, 4. American Cancer Society, Atlanta.
2. O'Connell MJ, Mailliard JA, Kahn MJ, et al. Controlled trial of fluorouracil and low dose leucovorin given 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 1997, 15:246-250.
3. Barone C Adjuvant chemotherapy of colon cancer current strategies. Eur J Cancer 2008, 6(Suppl):60-63.
4. Van Cutsem E, Costa F Progress in the adjuvant treatment of colon cancer. Has it influenced clinical practice?. JAMA 2005, 7:2758-2760.
5. O'Connell MJ Oxaliplatin or irinotecan as adjuvant therapy for colon cancer: the results are in. J Clin Oncol 2009, 27:3082-3084.
6. Buyse M, Zelentach-Jacquotte A, Chalmers TC Adjuvant therapy of colorectal cancer. Why we still don't know?. JAMA 1988, 259:3571-3578.
7. Wolmark N, Fisher B, Rockette H, et al. Postoperative adjuvant chemotherapy or BCG for colon cancer: results from NSABP protocol C-01. J Natl Cancer Inst 1988, 80:30-36.
8. Laurie JA, Moertel CG, Fleming TR, et al. Surgical adjuvant therapy of large bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil; The North Central Cancer Treatment Group and the Mayo Clinic. J Clin Oncol 1989, 7:1447-1456.
9. Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990, 322:352-358.
10. Wolmark N, Rockette H, Fisher B, et al. The benefit of leucovorin modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol 1993, 11:1879-1887.
11. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) Investigators Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 1995, 345:939-944.
12. Haller DG, Catalano P, Macdonald JS Fluorouracil, leucovorin and levamisole adjuvant therapy for colon cancer: five year final report of INT-0089. Proc ASCO 1998, 17:256.
13. Wolmark N, Rockette H, Mamounas E, et al. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole and fluoro-uracil, leucovorin and levamisole in patients with Dukes B and C carcinoma of the colon. Results from National Surgical Adjuvant Breast and Bowel Project protocol C-04. J Clin Oncol 1999, 17:3553-3559.
14. Andrè T, Colin P, Louvet C, et al. Semimonthly vs monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomised trial. J Clin Oncol 2003, 21:2896-2903.
15. Carrato A, Kohne C, Bedenne L, et al. Folinic acid modulated bolus 5 FU or infusional 5 FU adjuvant treatment of patients of UICC stage III colon cancer: preliminary analysis of the PETACC 2 study. Proc ASCO 2006, 24:18s.
16. Saini A, Norman AR, Cunningham D, et al. Twelve weeks of protracted venous infusion of fluorouracil is as effective as 6 months of bolus 5 FU and folinic acid as adjuvant treatment in colorectal cancer. Br J Cancer 2003, 16:1859-1865.
17. Twelves C, Wong A, Nowacki MP Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005, 352:2696-2704.
18. Lembresky BC, Wieand HS, Petrelli NJ, et al. Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from NSABP protocol C-06. J Clin Oncol 2006, 24:2059-2064.
19. Andrè T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, 5 fluorouracil and leucovorin as adjuvant treatment of colon cancer: results of the international randomized MOSAIC trial. N Engl J Med 2004, 350:2343-2351.
20. Kuebler JP, Wieand HS, O'Connell MJ, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 2007, 25:2198-2204.
21. Haller DG, Cassidy J, Tabernero J, et al. Efficacy findings from a randomized phase III trial of capecitabine plus oxaliplatin versus bolus 5-FU/LV for stage III colon cancer (NO16968): impact of age on disease free survival. Proc ASCO 2010;20: Abst. 3521.
22. Van Cutsem E, Labianca R, Bodoky G, et al. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol 2009, 27:3117-3125.
23. Andrè T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009, 27:3109-3116.
24. O'Connell MJ, et al. Survival following recurrence in stage II and III colon cancer: finding from the ACCENT data set. J Clin Oncol 2008, 26:2336-2341.
25. De Gramont A, Hurbard J, Shi Q, et al. Association between disease free survival and overall survival when survival is prolonged after recurrence in patients receiving cyotoxic adjuvant therapy for colon cancer: simulations based on the 20800 patients Accent data set. J Clin Oncol 2010, 28:460-465.
26. Saltz LB, Niedzwiecki D, Hollis D, et al. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J Clin Oncol 2007, 25:3456-3461.
27. Ycou M, Raoul JL, Douillard JY, et al. A phase III trial of LV5FU2+CPT11 vs LV5FU2 alone in adjuvant high risk colon cancer. Proc ASCO 2005, 36:16s. [abstract 3502].
28. Andrè T, Afchain P, Barrier A, et al. Current status of adjuvant therapy for colon cancer. Gastrointest Cancer Res 2007, 1:90-97.
29. IMPACT B2 investigators Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. J Clin Oncol 1999, 17:1356-1363.
30. Figueredo A, Charrette M, Maroun J, et al. Adjuvant therapy for stage II colon cancer: a systematic review from the Cancer Care Ontario Program in Evidence-Based Care's Gastrointestinal Cancer Disease Site Group. J Clin Oncol 2004, 22:3395-3407.
31. Gill S, Loprinzi CL, Sargent DJ, et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?. J Clin Oncol 2004, 22:1797-1806.
32. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 2007, 370:2020-2029. Quasar collaborative group.
33. Alberts SR, Sargent DJ, Smyrk TC, et al. Adjuvant mFOLFOX6 with or without Cetuximab (Cmab) in KRAS wild-type (WT) patients (pts) with resected stage II colon cancer (CC): result from NCCTG Intergroup Phase III Trial N0147. J Clin Oncol 2010, 28(Suppl 18):959s.
34. Ferrara N, Gerber HP, LeCouter J The biology of VEGF and its receptors. Nat Med 2003, 9:669-676.
35. Wolmark N, Yothers G, O'Connell MJ, et al. A phase III trial comparing mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: results of NSABP Protocol C-08. J Clin Oncol 2009, 27(Suppl 15):793s.
36. Umar A, Boland CR, Terdinam JP, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004, 96:261-268.
37. Koopman M, Kortman GA, Mekenkamp L, et al. Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. Br J Cancer 2009, 100:266-273.
38. Gryfe R, Kim H, Hsieh ETK, et al. Tumour microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med 2000, 342:69-77.
39. Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil based adjuvant chemotherapy for colon cancer. N Engl J Med 2003, 349:247-257.
40. Popat S, Hubner R, Houlston RS Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 2005, 23:609-618.
41. Roth AD, Tejpar S, Yan P, et al. Stage-specific prognostic value of molecular markers in colon cancer: Results of the translational study on the PETACC 3-EORTC 40993-SAKK 60-00 trial. J Clin Oncol (meeting abstract) 2009, 27:4002.
42. Kerr D, Gray R, Quirke P, et al. A quantitative multigene RT-PCR assay for prediction of recurrence in stage II colon cancer: selection of the gene in four large studies and results of the independent, prospectively designed QUASAR validation study. J Clin Oncol 2009, 25(15 Suppl):169s.
43. Elsaleh H, Iacoppetta B Microsatellite instability is a predictive marker for survival benefit from adjuvant chemotherapy in a population-based series of stage III colorectal carcinoma. Clin Colorectal Cancer 2001, 1:104-109.
44. Jover R, Zapater P, Castells A, et al. The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status. Eur J Cancer 2009, 45:365-373.
45. Bertagnolli MM, Niedzwiecki D, Compton CC, et al. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. J Clin Oncol 2009, 27:1814-1821.
46. Tejpar S, Bosman F, Delorenzi M, et al. Microsatellite instability (MSI) in stage II and III colon cancer treated with 5FU-LV or 5FU-LV and irinotecan (PETACC 3-EORTC 40993-SAKK 60/00 trial). J Clin Oncol (meeting abstract) 2009, 27:4001.
47. French AJ, Sargent DJ, Burgart LJ, et al. Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer. Clin Cancer Rev 2008, 14:3408-3415.
48. Blanke CD Perforation and stage II colon cancer: is it always high risk?. Gastrointest Cancer Res 2008, 2:103-104.
49. Collacchio TA, Niedzwiecki D, Compton C, et al. Phase III trial of adjuvant immunotherapy with MOAb 17-1A following resection for stage II adenocarcinoma of the colon (CALGB 9581). J Clin Oncol (meeting abstract) 2004, 22:3522.
50. Boland CR, Thibodeau SN, Hamilton SR, et al. A National Cancer Institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998, 58:5248-5257.
51. de Gramont A, Boni C, Navarro M, et al. Oxaliplatin/5FU/LV in adjuvant colon cancer: Updated efficacy results of the MOSAIC trial, including survival, with a median follow-up of six years. J Clin Oncol (meeting abstract) 2007, 26:4007.
52. Wolmark N, Yothers G, O'Connell MJ, et al. A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: Results of NSABP Proto08. J Clin Oncol (Meeting abstract) 2009, 27:LBA4.
53. Ogino S, Meyerhardt JA, Irahara N, et al. KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803. Clin Cancer Res 2009, 15:7322-7329.
54. Westra JL, Schaapveld M, Hollema H, et al. Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients. J Clin Oncol 2005, 23:5635-5643.
55. Pitari GM, Li P, Lin JE, et al. The paracrine hormone hypothesis of colorectal cancer. Clin Pharmacol Ther 2007, 82:441-447.
56. Waldman SA, Hyslop T, Schulz S, et al. Association of GUCY2C expression in lymph nodes with time to recurrence and disease-free survival in pN0 colorectal cancer. JAMA 2009, 301:745-752.
57. Vogelstein B, Lane D, Levine AJ Surfing the p53 network. Nature 2000, 408:307-310.
58. Elsaleh H, Powell B, McCaul K, et al. P53 alteration and microsatellite instability have predictive value for survival benefit from chemotherapy in stage III colorectal carcinoma. Clin Cancer Res 2001, 7:1343-1349.
59. Petersen S, Thames HD, Nieder C, et al. The results of colorectal cancer treatment by p53 status: Treatment-specific overview. Dis Colon Rectum 2001, 44:322-333.
60. Munro AJ, Lain S, Lane DP P53 abnormalities and outcomes in colorectal cancer: A systematic review. Br J Cancer 2005, 92:434-444.
61. Resnick MB, Routhier J, Konkin T, Sabo E, Pricolo VE Epidermal growth factor receptor, c-MET, beta-catenin, and p53 expression as prognostic indicators in stage II colon cancer: a tissue microarray study. Clin Cancer Res 2004, 10:3069-3075.
62. Mulder JW, Baas IO, Polak MM, Goodman SN, Offerhaus GJ Evaluation of p53 protein expression as a marker for long-term prognosis in colorectal carcinoma. Br J Cancer 1995, 71:1257-1262.
63. Rajagopalan H, Bardelli A, Lengauer C, et al. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 2002, 418:934.
64. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954.
65. Roth AD, Tejpar S, Delorenzi M, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: Results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 2010, 28:466-474.
66. Bardia A, Loprinzi C, Grothey A, et al. Adjuvant chemotherapy for resected stage II and III colon cancer: comparison of two widely used prognostic calculators. Semin Oncol 2010, 37:39-46.